JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC

In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer" by Bradley, et al published October 13, 2025.

TRANSCRIPT TO COME

 

 

DISCLOSURES

Dr. Bradley
Honoria: Mevion Medical Systems, Inc.
Consulting or Advisory Role: Varian, Inc, Genentech, Inc.
Research Funding: Varian Medical Systems

Dr. Cali
Research Funding Company: BeiGene, Nuvalent, Inc., Astra Zeneca